The American Journal of Medicine
Volume 123, Issue 4, Supplement , Pages S39-S46, April 2010

Health Economics of Use Fluoroquinolones to Treat Patients with Community-Acquired Pneumonia

  • Marcos I. Restrepo, MD, MSc

      Affiliations

    • Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    • Division of Pulmonary and Critical Care Medicine, Department of Medicine, VERDICT/South Texas Veterans Health Care System, Audie L. Murphy Division, San Antonio, Texas, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Marcos I. Restrepo, MD, MSc, Division of Pulmonary and Critical Care Medicine, VERDICT at South Texas Veterans Healthcare System, Audie L. Murphy Division, University of Texas Health Science Center, 7400 Merton Minter Boulevard (11C6), San Antonio, Texas 78229
    • ,
  • Christopher R. Frei, PharmD, MSc

      Affiliations

    • Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    • Division of Pharmacotherapy, College of Pharmacy, University of Texas at Austin, Austin, Texas, USA

Abstract 

Respiratory diseases account for approximately 10% of all hospital admissions in the United States. Pneumonia constitutes 35% of these cases, with an average length of stay (LOS) of 5.1 days. It is estimated that $8.4 billion to $10 billion of all annual US hospital expenditures are attributable to community-acquired pneumonia (CAP). As such, medical decisions, including empiric antibiotic choice, potentially exert an impact on hospital LOS and associated costs. In this review, we focus on the empiric antibiotic choices and associated costs of treatment for hospitalized patients with CAP, focusing on the use of fluoroquinolone therapy as recommended by the CAP guidelines.

Keywords: Fluoroquinolones, β-Lactams, Macrolides, Medical economics, Respiratory disorders

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

 Dr. Restrepo is supported by a Department of Veterans Affairs Veterans Integrated Service Network 17 new faculty grant and by Grant No. KL2 RR025766 from the National Institutes of Health (NIH). Dr. Frei is supported by a Loan Repayment award from the National Institute of Allergy and Infectious Diseases of the NIH; salary support from The University of Texas at Austin College of Pharmacy and research support from Astra Zeneca, Elan, and Ortho-McNeil Janssen. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.

PII: S0002-9343(10)00100-2

doi:10.1016/j.amjmed.2010.02.005

The American Journal of Medicine
Volume 123, Issue 4, Supplement , Pages S39-S46, April 2010

Article Tools

* Image Usage & Resolution